Zacks Investment Research on MSN
TG Therapeutics begins Phase II study with Briumvi in schizophrenia
TG Therapeutics TGTX announced that it has initiated a phase II study evaluating Briumvi (ublituximab-xiiy) for the treatment ...
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results